A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors

Inclusion Criteria:

- Subject has histologically confirmed malignancy that is metastatic or unresectable

- Subject has disease that is assessable by tumor marker, physical, or radiologic means

- Subject is at least 18 years old

- Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)

- Subject has a life expectancy ≥ 3 months

- Subject has normal organ and marrow function

- Subject gives written informed consent

- Subject must use an accepted method of contraception during the study

- Female subjects of childbearing potential must have a negative pregnancy test

Exclusion Criteria:

- Subject has received anticancer treatment within 30 days of first dose of XL647

- Subject has received another investigational agent within 30 days of first dose of
XL647

- Subject has known brain metastases

- Subject has corrected QT interval (QTc) of > 0.45 seconds

- Subject is currently receiving anticoagulation therapy with warfarin

- Subject has uncontrolled intercurrent illness

- Subject is pregnant or breastfeeding

- Subject has known HIV